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Environmental and other xenobiotic agents can cause autoimmunity. Examples include
drug-induced lupus, toxic oil syndrome, and contaminated L-tryptophan ingestion. Numerous
mechanisms, based on in vitro evidence and animal models, have been proposed to explain how
xenobiotics induce or accelerate autoimmunity. The majority of these can be divided into three
general categories. The first is those inhibiting the processes involved in establishing tolerance by
deletion. Inhibiting deletion can result in the release of newly generated autoreactive cells into the
periphery. The second mechanism is the modification of gene expression in the cells participating in
the immune response, permitting lymphocytes to respond to signals normally insufficient to initiate
a response or allowing the antigen-presenting cells to abnormally stimulate a response. Abnormal
gene expression can thus disrupt tolerance maintained by suppression or anergy, permitting
activation of autoreactive cells. The third is the modification of self-molecules such that they are
recognized by the immune system as foreign. Examples illustrating these concepts are presented,
and related mechanisms that have the potential to similarly affect the immune system are noted.
Some mechanisms appear to be common to a variety of agents, and different mechanisms appear
to produce similar diseases. However, evidence that any of these mechanisms are actually
responsible for xenobiotic-induced human autoimmune disease is still largely lacking, and the
potential for numerous and as yet unidentified mechanisms also exists. Key words: anergy,
autoimmunity, deletion, mechanisms, suppression, tolerance, xenobiotic.- Environ Health
Perspect 107(suppl 5):737-742 (1999).
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Irrefutable evidence shows that xenobiotic
agents can cause autoimmunity. Examples
include drug-induced lupus (1), toxic oil syn-
drome (2,3), and contaminated L-tryptophan
ingestion (4,5). Numerous mechanisms,
based on in vitroevidence and animal models,
have been proposed to explain how xenobi-
otics may induce or accelerate autoimmunity.
This report is a review ofpotential mecha-
nisms, which are illustrated with specific
examples. However, despite the body oflitera-
ture reviewed herein, evidence that the pro-
posed mechanisms are operant in people with
xenobiotic-induced autoimmunity is still
largely lacking. For example, the mechanisms
involved in the pathologic processes by which
drugs induce lupuslike autoimmunity have
not yet been elucidated in humans. The mul-
tiple potential mechanisms, together with our
lack ofunderstanding ofmechanisms involved
in the human diseases, highlight a need for
further study in this area.
Tolerance
Most proposed mechanisms ofautoimmunity
involve cells ofthe immune system escaping
tolerance. Tolerance refers to the phenome-
non in which the immune system responds to
and eliminates foreign organisms or molecules
but ignores the host. Autoimmunity results
when homeostatic mechanisms fail and the
immune system responds to the host. The tol-
erance ofhost molecules is not inherent to the
immune system but is acquired during devel-
opment and actively maintained throughout
life. Multiple mechanisms are used to silence
potentially autoreactive lymphocytes. Most of
the mechanisms involve either deletion,
anergy, or suppression (6-8). Deletion refers
to the elimination ofself-reactive T and B
lymphocytes by apoptosis and occurs during
maturation as well as in mature lymphocytes.
By its nature, deletion is irreversible, but the
processes involved must be continuously
maintained to prevent the generation ofnew
autoreactive cells. Anergy is the induced unre-
sponsiveness to conventional antigenic stimu-
lation, and the anergic lymphocytes survive as
functionally inactive cells. T-cell anergy can be
induced by multiple mechanisms such as anti-
gen presentation in the absence ofcostimula-
tory signals like those provided by the
B7/CD28 molecules, which normally support
T-cell activation through the T-cell antigen
receptor (TCR) (9). Anergy can be reversible
(6-10) and thus also requires continuous
maintainence. Suppression is also an active
process in which responses to self-antigens are
suppressed by other cells and factors derived
from them (8). These processes are discussed
in greater detail in the sections that follow.
The active nature of immune tolerance
implies that events or chemicals that inhibit
the mechanisms maintaining tolerance have
the potential ofallowing the generation or
activation ofautoreactive cells, with the subse-
quent development ofautoimmunity. Because
the systems involved are complex, there are a
correspondingly large number ofways by
which tolerance can be disrupted.
Mechanisms Disrupting
Tolerance
Most ofthe mechanisms by which xenobiotics
disrupt tolerance can be grouped into three
general categories. The first is those inhibiting
the processes involved in establishing tolerance
by deletion, permitting release ofautoreactive
cells in the periphery. The second is modifica-
tion of gene expression in the cells participat-
ing in the immune response, permitting
lymphocytes to respond to signals normally
insufficient to initiate a response or allowing
the antigen-presenting cells to abnormally
stimulate a response. Abnormal gene expres-
sion can thus disrupt tolerance maintained by
anergy or suppression and permit activation of
autoreactive cells. The third is the modification
ofself-molecules such that they are recognized
by the immune system as foreign. These cate-
gories are not necessarily mutually exclusive,
and some xenobiotics may affect tolerance by
multiple mechanisms. Examples illustrating
these concepts are presented in the sections
that followand are summarized inTable 1.
Abnormalities ofTolerance
Induction by Deletion
The Iprand gld mouse strains offer two ofthe
clearest demonstrations that abnormalities of
deletion can result in systemic autoimmunity
(11-13). These strains develop a lupuslike
disease that includes the production ofanti-
nuclear antibodies as well as massive lymphoid
proliferation. The Iprand gldmutations result
in the functional loss of genes encoding Fas
and Fas ligand (FasL), respectively, which are
involved in triggering apoptotic cell death
(11,12). During normal thymic development,
potentially autoreactive thymocytes are elimi-
nated by apoptosis, triggered by Fas-FasL
interactions (central tolerance). A similar
process can occur in the periphery (peripheral
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Table 1. Potential mechanisms of xenobiotic-induced
autoimmunity.
Xenobiotics may breaktolerance by
Inhibiting deletion ofautoreactive cells
Modifying gene expression to reverse anergy or
prevent suppression by
Modifying chromatin structure
Stimulating or inhibiting signaling molecules
Stimulating or inhibiting cytokine receptors
Acting as endocrine disruptors
Altering antigenicity of self-molecules by
Acting as haptens
Cleaving self-molecules to generate cryptic epitopes
Acting as superantigens
tolerance) (12). Mice with mutations in Fas
or FasL fail to eliminate the autoreactive
T cells, resulting in the subsequent develop-
ment ofautoimmunity (11-13). Humans
with defects in these genes develop auto-
immune hemolytic anemia, thrombocytope-
nia, and neutropenia, supporting the
association with autoimmunity (14). These
examples provide persuasive evidence that
inhibiting deletion can produce an auto-
immune disease and raise the possibility that
xenobiotics might have a similar effect.
Because the mechanisms identifying the
potentially autoreactive cells are not well
understood, the possibility also exists that
xenobiotics could disrupt the selection
process, resulting in release of autoreactive
cells. However, this will remain speculative
until the mechanisms identifying the auto-
reactive cells are bettercharacterized.
Other animal models demonstrate that
exogenous agents can affect central tolerance
to produce autoimmunity. Cyclosporine A
(CsA), an immunosupressant believed to act
by blocking T-cell signal transduction (15),
can interfere with central tolerance induction.
Lethally irradiated, bone marrow-reconsti-
tuted mice will develop autoimmunity if
given high-dose CsA. These mice develop
T-lymphocyte and macrophage-rich inflam-
matory lesions in the colon, stomach, liver,
and pancreas. The autoimmune disease can
be tranferred by injecting T lymphocytes
from affected mice into naive genetically
identical (syngeneic) recipients, indicating
that autoreactive lymphocytes are responsible.
In this model, CsA appears to prevent thymic
deletion by blocking signaling during the
negative thymic selection step. This prevents
activation ofautoreactive thymocytes by self-
molecules and thus prevents their subsequent
apoptotic elimination (16).
Radiation can also interfere with tolerance.
High-dose fractionated total lymphoid irradia-
tion causes a variety oforgan-specific autoim-
mune diseases in BALB/c mice. These indude
autoimmune gastritis with antiparietal cell
antibodies, thyroiditis with antithyroglobulin
antibodies, sialoadenitis, and orchitis, depend-
ing on the radiation dose. CD4+ T cells from
these mice adoptively transfer the auto-
immunity to naive syngeneic mice, suggesting
that irradiation is interfering with mechanisms
inducing T-cell tolerance or anergy in these
mice (17). Neonatal thymectomy produces a
similar CD4+ T-cell-mediated autoimmune
disease (18), which further supports this con-
cept. An autoimmune disorder characterized
by skin rash and occasionally autoimmune
thrombocytopenia or hemolytic anemia has
been reported in breast cancer patients receiv-
ing autologous stem cell transplantations
(19), suggesting that a similar disorder may
occur in humans.
Disruption ofcentral tolerance mayplay a
role in drug-induced lupus. Procainamide can
be metabolized to procainamide hydroxy-
lamine (PAHA) by reactive oxygen species.
Injecting PAHA into the thymus of non-
autoimmune mice induces IgG anti-
chromatin antibodies that are sustained over
several months (20). In vitro studies have
shown that PAHA transiently prevents the
induction ofanergy in mature T lymphocytes
(21), suggesting that PAHA may similarly
prevent tolerance established during thymic
development. The PAHA model illustrates
the principle that small organic molecules can
disrupt central tolerance to result in the pro-
duction ofantinuclear antibodies. However,
evidence that this process contributes to
human drug-induced lupus is still lacking.
Modification ofCellular Gene
Expression
Evidence indicates that xenobiotics can break
tolerance by modifying gene expression in cells
participating in immune responses. In several
ofthese systems a valid link to autoimmunity
has been established using animal models.
Xenobiotics can modify gene expression in
lymphocytes as well as antigen-presenting cells
by acting on receptors, their signaling path-
ways, or at the DNA level. Examples indude
endocrine disrupters and agents that mimic or
inhibit the effects ofcytokines on their recep-
tors, agents affecting kinases and phosphatases
to activate or inhibit signaling, and agents that
modify chromatin structure to affect gene
expression. Changes in gene expression caused
by any ofthese mechanisms may either break
tolerance by modifying mechanisms involved




Changes in T-cell DNA methylation have
been implicated in the development of
autoimmunity. DNA methylation refers to
thepostsynthetic methylation ofdeoxycytosine
(dC) residues at the 5 position. Methylation of
dC residues in promoter sequences can
suppress gene expression through mechanisms
involvingspecific methylcytosine-bindingpro-
teins and changes in chromatin structure
(22,23). These changes prevent transcription
factors from interacting with promoter
sequences, thereby suppressing gene expres-
sion. DNA methylation patterns are estab-
lished during ontogeny, then maintained
through subsequent mitoses by DNA methyl-
transferase (MTase), which replicates methyla-
tion patterns in newlysynthesized DNA (24).
Pharmacologic inhibition of DNA MTase
with the nucleoside analog 5-azacytidine
causes overexpression ofthe adhesion mole-
cule lymphocyte function-associated antigen 1
(LFA-1) as well as autoreactivity in cloned,
antigen-specific CD4+ T cells (25). The
autoreactivity is due to the LFA-1 overexpres-
sion because causing LFA-1 overexpression by
transfection causes a similar autoreactivity
(26,27). Therapeutic concentrations ofpro-
cainamide and hydralazine also inhibit DNA
methylation, increase LFA-1 expression, and
cause autoreactivity in T-cell lines (26-29).
Adoptive transfer ofmurine T cells rendered
autoreactive by treatment with 5-azacytidine,
procainamide, orhydralazine into nonautoim-
mune syngeneic mice leads to widespread
autoimmune disease with anti-DNA anti-
bodies, proliferative glomerulonephritis, pul-
monary alveolitis, liver lesions resembling
primary biliary cirrhosis, and histologic
changes in the brain resembling central ner-
vous system lupus (30,31). Ultraviolet light,
implicated in triggeringlupus flares, has asim-
ilar effect on T cells (26). These findings sug-
gest a model for xenobiotic induction of
lupuslike autoimmunity in which inhibiting
DNA methylation in T lymphocytes modifies
gene expression and induces autoreactivity,
and the autoreactive cells can then cause a
lupuslike disease. In support ofthis, T cells
from patients with active lupus have a reduc-
tion oftotal genomic deoxymethylcytosine
content and overexpress LFA-1 on an autore-
active T-cell subset, the size ofwhich strongly
correlates with disease activity (25,32).
However, these findings have yet to be identi-
fied in patientswithdrug-inducedlupus.
Xenobiotics can also affect histone
acetylation with effects on gene expression.
The acetylation ofhistones is associated with
gene expression, whereas deacetylation corre-
lates with transcriptional suppression (33).
An association between DNA methylation
and histone deacetylation has been proposed,
as methylcytosine-binding proteins physically
associate with histone deacetylase, directing
the deacetylase activity to regions ofchro-
matin destined for inactivation (23). Similar
to DNA MTase, histone deacetylase is sus-
ceptible to inhibition by xenobiotics with
effects on gene expression, which are
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frequently synergistic with DNA MTase
inhibitors (34). Inhibitors of histone
deacetylase include sodium butyrate (35) and
trichostatin A (34,35). Treating cells with
histone deacetylase inhibitors can alter cell
morphology, induce hemoglobin F produc-
tion, and modify T-cell cytokine expression
(34,36). Altered cytokine production can
affect tolerance (vide infra), suggesting a
mechanism by which histone acetylase
inhibitors might contribute to autoimmunity.
Histone deacetylase inhibitors also reactivate
retroviral expression (36). Reactivation of
latent retroviruses has been proposed as a
mechanism contributing to the development
ofautoimmunity (37), although this link to
autoimmunityalso remains theoretical.
Adsenosine disphosphate (ADP)-
ribosylation is yet another mechanism
involved in chromatin formation with effects
on gene expression. Poly(ADP-ribosyl)
(PADPR) transferase is a chromatin-bound
enzyme that catalyzes the transfer ofADP-
ribose moieties from nicotinamide adenine
dinucleotide (NAD) to chromatin proteins,
principally histones HI and H2B. ADP-
ribosylation prevents methylation ofgenes by
modifying histone HI (38,39), thus partici-
pating with DNA methylation and histone
acetylation in modifying chromatin structure.
Several authors have implicated changes in
polyADP-ribosylation with autoimmunity.
Histones coupled to nucleic acids exhibit aug-
mented immunogenicity, and antibodies
against poly(ADP-ribose) occur in idiopathic
systemic lupus erythematosus (SLE) and drug-
induced lupus (40). In addition, both
procainamide and hydralazine upregulate
PADPRpolymerase activity in lymphocyte cell
lines (41), which could inhibit DNA methyla-
tion indirectly (38,39). Besides affecting
chromatin, poly(ADP-ribosylation) of
T-cell-surface proteins including LFA-1,
CD8, CD27, CD43, CD44, and CD45 is
known to occur. NAD treatment increases
poly(ADP-ribosylation) ofcell-surface proteins
and inhibitsantigen-stimulated responses (42).
Further, NAD-treated cells fail to efficiently
home to lymphoid organs, suggesting direct
effects on adhesion molecule expression or
function (42). Finally, a gene contributing to
familial lupus has recently been identified as
PADPR polymerase (43), and defects in
PADPR polymerase have been associated with
idiopathic SLE (44,45). These observations
provide tantalizing clues as to how ADP-ribo-
sylation might contribute to autoimmunity,
but again, mechanisms directlylinkingchanges
in histone ADP-ribosylation to autoimmunity
have notbeen established.
In summary, DNA methylation, histone
acetylation, and histone polyADP-ribosyla-
tion all contribute to chromatin structure and
thereby to gene regulation. All are susceptible
to modification by xenobiotics, usually in a
synergistic fashion, and at least two lupus-
inducing drugs, procainamide and
hydralazine, have effects on this regulatory
mechanism. This area appears to represent a
potentially fruitful approach to modification
ofcells by xenobiotics, with direct relevance
to autoimmunity.
Endocrine Disruptors
Considerable experimental evidence supports
an immunomodulatory role forfemale sexhor-
mones (46). Females generally have more
robust humoral andcellular immune responses
than males. This has been proposed as an
explanation for the increased prevalence of
autoimmune disease in women (46). Female
sex hormones have been direcdy implicated in
contributing to increased disease severity in
murine models oflupus (46-48), and oral
contraceptives have been associated with
human lupus (49). Thymocytes, T cells,
B cells, macrophages, and endothelial cells
express estrogen receptors (50,51), and treat-
ing immunocytes with estrogens causes
enhanced protooncogene expression, modified
cytokine production, changes in immune cell
apoptosis, and altered adhesion molecule
expression, which may augment an immune
response (50). Recently, lymphocytes have
been shown to traffic differently in male
and female mice, and the differential traffick-
ing to be directly related to increased severity
of autoimmunity in the female mice.
Oophorectomy diminished disease severity
and produced a trafficking pattern resembling
that ofmales, providing yet another mecha-
nism by which female sex steroids may affect
autoimmunity (52). This sensitivity ofthe
immune system to hormonal modulation sug-
gests a mechanism by which xenobiotic
endocrine disrupters may contribute to
autoimmunity. Numerous examples ofchemi-
cals with estrogenlike activity have been
described and include resveratrol, aphytoestro-
gen present in grapes and a variety ofmedici-
nal plants (53), and phenol red, a widely used
pH indicator (54). Others are discussed else-
where (53). Although the mechanism by
which xenobiotic endocrine disrupters con-
tribute to autoimmunity remains obscure, the
potential contribution of these agents to
autoimmunity remains avalid concern.
Cytokines
Cytokines can also modify gene expression to
break tolerance. For example, interferon
(IFN)-y upregulates class II major histocom-
patability complex (MHC) molecule expres-
sion on nonlymphoid tissues such as murine
intestinal epithelial cells, allowing antigen pre-
sentation to CD4+ T lymphocytes (55).
Overexpressing IFN-yon islet cells leads to the
development ofinsulitis and diabetes in mice,
presumably by this mechanism, demonstrating
the pathologic consequences ofinappropriate
cytokine secretion or other activity that
induces expression ofthese molecules (56).
Xenobiotics have the potential ofhaving simi-
lareffects on cells. Forexample, pharmacologic
concentrations ofalimemazine, a phenoth-
iazene, induces de novo MHC class II mole-
cule expression on cultured thyroid epithelial
cells, offering a novel explanation for the
induction ofthyroidgland-specific autoreactiv-
ity (57), although in vivo evidence supporting
this hypothesis remains to be established.
Otherxenobiotics could havesimilareffects.
In a related example, exposure to silica has
been associated with the development of
fibrotic and other connective tissue diseases,
including rheumatoid arthritis, scleroderma,
and lupus (58). Pulmonary interstitial fibrosis
is also encountered. In vitro studies have
shown that silica can activate macrophages to
secrete cytokines including interleukin (IL)-1
and tumor necrosis factor (TNF), and increase
surface Fcreceptorand MHC class II molecule
expression (58,59). It has been proposed that
secretion ofthese cytokines and possibly other
functions of silica-activated macrophages
contribute to the fibrosis and possibly the
induction ofsilica-induced autoimmunity.
Xenobiotics could also interfere with
tolerance mediated by suppression, through
effects on cytokines and chemokines. The
concept ofimmune suppression has been res-
urrected by the recent observation that certain
cytokines and chemokines have suppressive
effects in selected systems. For example, trans-
forming growth factor P (TGF-,) can sup-
press immune responses, and knockout mice
lackingTGF-P develop inflammatory lesions
in various organs including the heart and
stomach (60,61). Local TGF-3 production
can also establish localized tolerance (62).
These observations raise the theoretical possi-
bility that xenobiotics interfering with TGF-,
actions could induce autoimmunity. Another
example involves T-cell subsets. CD4+ T cells
can be divided into subsets defined by their
cytokine secretion repertoire. T-helper (Th)0
precursor cells produce a relatively wide vari-
ety ofcytokines but mature into Th1 cells
participating in delayed-type hypersensitivity
responses and secreting IFN-y, IL-2, and lym-
photoxin, or mature into Th2 cells promoting
antibody synthesis and secreting IL-4, IL-5,
IL-6, and IL-10 (63). The maturation ofThO
into Thl or Th2 cells can be influenced by
cytokines, with IFN-y suppressing IL-4 pro-
duction and promoting Thl differentiation,
and IL-4 and IL-10 suppressing IFN-y and
promoting Th2 differentiation (63). This
paradigm has been successfully applied to
experimental systems such as collagen-induced
arthritis, where a Thl response is responsible
for disease manifestations and cytokines
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promoting Th2 differentiation suppress the
disease (64). Xenobiotics have thepotential to
similarly modify immune responses. A recent
example is the demonstration that DNA
methylation inhibitors together with histone
deacetylase inhibiors will modify IFN-,y and
IL-4 expression inThi andTh2 cells (65).
Modification ofchemokines can have a
similar regulatory effect. For example, corneal
endothelial and lens epithelial cells express lit-
tle or no MHC dass I molecules and are thus
susceptible to natural killer (NK) cell-medi-
ated killing. This is prevented by local
inhibitory factors in the aqueous humor such
as macrophage inhibition factor (MIF),
which prevents perforin granule release from
NK cells; authors have proposed that this
suppressive mechanism prevents immune-
mediated destruction ofthese cells (66).
Agents interfering with MIF action would
thus permit an autoimmune reaction.
In another example ofsuppression, TNF
inhibits lupus nephritis in animal models,
suggesting a suppressive role for this cytokine
in lupuslike diseases (67). Administering
anti-TNF agents to patients with rheumatoid
arthritis has induced lupuslike serologies
(68), raising the possiblity that xenobiotic
agents that inhibit TNF production or action
could remove this suppressive effect and con-
tribute to the development oflupuslike dis-
eases, further supporting the concept that
interference with suppression may contribute
to human autoimmunity.
SignalingModifiers
There are examples ofxenobiotics modifying
signaling with the potential ofcontributing to
autoimmunity. Small organic molecules capa-
ble ofspecifically inhibitingsignalingpathways
have recendy been described, raising the possi-
bility that xenobiotics could have similar
effects. Forexample, aselective Mekl inhibitor
is available that inhibits signaling through the
Ras-MAPK pathway (69). Treating T lym-
phocytes with this compound decreases DNA
MTase levels, which theoretically contributes
to thedevelopmentoflupuslike diseases (70).
Programmed cell death is also regulated by
signaling pathways that could besusceptible to
interference by xenobiotics similar to those
affecting other signaling pathways. The obser-
vation that benzo[a]pyrenes alter signaling
(71) and induce apoptosis (72) in vitro sup-
ports this concept. Abnormal cell death with
release ofnormally sequestered antigens could
theoretically contribute to autoimmunity.
Release ofsequestered antigens as the antigenic
stimulus in lupuslike diseases has support from
the DNA hypomethylation model ofdrug-
induced lupus. In this model, the autoreactive
T cells home to lymphoid tissue where they
induce macrophage apoptosis. Release ofDNA
from the apoptotic cells has been proposed as
the source ofantigenic DNA for anti-DNA
antibody synthesis in this model (30,31,52).
Others have proposed that apoptotic cells pro-
vide autoantigens aswell (73,74).
Finally, small organic molecules can also
modify gene expression directly. Pyrrole and
imidazone polyamides can permeate living
cells and inhibit transcription of specific
genes (75), which could potentially play a
role in autoimmune as well as other diseases.
The immunologic effects ofthese agents have
notyetbeen explored.
The DNA hypomethylation, endocrine
disruption, and cytokine models all demon-
strate that modification ofcells participating
in immune responses can contribute to
autoimmunity. The number of potential
mechanisms bywhichxenobiotics can modify
cells is large. It is likely that as yet unantici-
pated mechanisms will be identified as our
understanding ofsignaling pathways and reg-
ulation of gene expression improves. This
topic represents an underdeveloped but
potentially interesting areafor study.
Antigen Modification
Another category ofpotential mechanisms for
xenobiotic-induced autoimmunity is the mod-
ification ofself-proteins to breaktoleranceand
induce an immune response. This concept has
its roots in early studies on haptens and has
been extended by the newer concepts ofcryp-
tic epitopes and epitope spreading. A cryptic
epitope is anewantigenicdeterminant, or epi-
tope, created by the cleaving ofa molecule.
Epitope spreading refers to the generation of
immune responses to antigenic determinants,
or epitopes, physically adjacent to the immu-
nizing epitope. Extensive experimental
evidence exists to support the concepts of
haptenization and cryptic epitopes in auto-
immunity, although as in the other proposed
mechanisms, direct proofofcausation needs
confirmation in patients or animals with
xenobiotic-induced diseases.
Haptenization
The general concept ofhaptenization is that
proteins can be chemically modified by com-
bination with small reactive compounds
called haptens, improving antigenicity. Early
studies demonstrated that covalent coupling
ofhaptens such as trinitrophenol to proteins
produced potent antigens (76). Urushiol, the
irritant in poison ivy, is a linically relevant
exampleofthis (76). Once a response is initi-
ated, the phenomenon ofepitope spreading
may occur, in which antigenic epitopes asso-
ciated with but physically distinct from the
hapten are progressively recognized by
responding T and B cells (77). The phenom-
enon ofepitope spreading is dearly demon-
strated in the development of the immune
response to small ribonucleoproteins in lupus
(78). The concept of haptenization of -
self-proteins, togetherwith epitope spreading,
has prompted the hypothesis that some xeno-
biotics induce autoimmunity to self-proteins
through asimilar mechanism.
Numerous examples illustrating this
concept have been described. Heavy metals
have been implicated in triggering some
forms ofautoimmunity (76). Heavy metal
ions ofmercury, gold, and nickel will bind
proteins, altering molecular and antigenic
properties. Mercuric chloride can induce
antifibrillarin antibodies in susceptible mouse
strains (79), and mercury ions will bind fib-
rillarin, potentially altering its antigenicity
(80). Hydralazine, procainamide, and to a
lesser degree, isoniazid and D-penicillamine
change the usual right-handed helical configu-
ration ofDNA (B DNA) to a more immuno-
genic left-handed helical configuration (Z
DNA) in vitro (81). This conversion has been
proposed as a mechanism contributing to the
development ofanti-DNAantibodies in drug-
induced lupus (81). Others have shown that
bioreactive metabolites ofphenytoin can cova-
lently bindandmodify MHC molecules (82).
These authors have proposed that the modi-
fied MHC molecules trigger a T-cell response
analogous to chronic graft versus host disease,
which has features ofa variety ofsystemic
autoimmune diseases including lupus,
rheumatoid arthritis, and sderoderma (83).
Similarly, oxidized metabolites ofvinyl chlo-
ride, implicated in inducing a sclerodermalike
disease, can bind sulfhydryl and amino
groups, which also potentially modifies anti-
genicity or function (84). However, persua-
sive evidence demonstrating that these
mechanisms contribute to autoimmunity
in vivoisstill lacking.
CrypticEpitopes
The cryptic epitope hypothesis is based on
experiments demonstrating that T cells will
respondto peptidefragmentsofself-molecules
not normally presented by antigen-presenting
cells. In general, proteins are degraded enzy-
matically and the resultant peptide fragments
presented in MHC molecules at the cell sur-
face. The immunesystem isusuallytolerant to
these self-peptides. However, ifthe peptides
are deaved differently then presented, novel
epitopes may be revealed and a response gen-
erated that may then also undergo epitope
spreading (85).
Gold ions are capable ofdeaving proteins
to generate cryptic epitopes. Gold salts are
implicated in autoimmune thrombocytopenia
and immune complex glomerulonephritis
through unknown mechanisms (76). Au(III),
a reactive metabolite ofgold, can cleave
bovine ribonudease A in vitro and generate
cryptic epitopes capable ofT-cell sensitization
(76). Heavy metals can alsocatalyzeoxidation
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reactions mediated by reactive oxygen species.
Several sderoderma autoantigens, including
topoisomerase I, the large subunit ofRNA
polymerase II, and the 70-kD subunit ofthe
Ul small nuclear ribonuclear protein are
cleaved by metal-catalyzed (Fe, Cu) oxidation
reactions, which may produce cryptic epi-
topes. Because episodic ischemia-reperfusion
such as that seen in the vasospasm associated
with sderoderma can generate reactive oxygen
species, this mechanism maytheoreticallycon-
tribute to some ofthe autoantibodies seen in
this disease (86), although in vivo evidence is
still lacking.
OtherMechanisms
Mechanisms proposed for infectious or other
etiologies of autoimmunity may also be
applied to xenobiotics, although experimental
evidence for these is largely absent. Antigenic
mimicry has been proposed as a mechanism
potentially causing autoimmunity (87). This
concept is usually applied to infectious agents
havingmolecules bearingoneormoreepitopes
resembling human antigens, such that
responses to the foreign antigen cross react
withself-antigens. It isconceivable thata xeno-
biotic could behave in a similar fashion
through hapteniceffects. Superantigens, which
noncovalently cross link MHC molecules with
the TCR, have also been nominated as poten-
tiallytriggeringautoimmunity (88). It is possi-
ble that haptenic modification ofa protein
binding MHC molecules or the TCR, such as
CD4 or CD8, could similarly stabilize
TCR-MHC interactions. Xenobiotic-induced
mutations in self-proteins could also occurand
serve as a novel antigen and induce a response
through epitope spreading. Finally, immune
responses to antigenic determinants on anti-
bodies or the TCR, known as idiotypes, have
been proposed as a mechanism contributing to
the development ofanti-DNA antibodies
(89), and it is possible thatthehaptenic modi-
fication ofan immunoglobulin idiotype could
induce an autoimmune response. Given the
large number ofways xenobiotics can poten-
tially modify proteins, additional mechanisms
probablyexist aswell.
Conclusions
Several condusions may be derived from this
review. First, the majority ofthe mechanisms
proposed for xenobiotic-induced autoimmu-
nity can be arbitrarily classified into three
broad categories: defects in lymphocyte dele-
tion, modification ofgene expression by the
cells participating in the immune response to
break tolerance, and direct interactions with
self-proteins leading to either expression of
new epitopes or unveiling ofcryptic epitopes.
These general concepts suggest additional
mechanisms by which xenobiotics might trig-
ger autoimmunity. Second, some mechanisms
may be common to a variety ofagents. The
ability ofdifferent metal ions to cleave pro-
teins and ofchemically distinct molecules to
inhibit DNAmethylation and induce autoim-
munity support this contention. Third, it
would appear that different mechanisms can
produce similar diseases. The intrathymic
injection ofPAHA and the treatment of
activated T cells with DNA methylation
inhibitors both induce anti-DNA antibodies,
most likely through distinct mechanisms.
Fourth, despite the large body ofliterature
addressing potential mechanisms by which
xenobiotics may induce autoimmunity, per-
suasive evidence demonstrating that these
mechanisms are actually operant in humans
with xenobiotic-induced autoimmunity is still
lacking. Finally, the potential for numerous
and as yet unidentified mechanisms exists,
highlighting a need for further work in this
area. It is hoped that the material presented at
the workshop Linking Environmental Agents
and Autoimmune Disease will stimulate fur-
therstudies onthistopic.
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